ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
about
Antineoplastic agents and thrombotic microangiopathy.Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.How we approach an acquired thrombotic thrombocytopenic purpura patient.How I treat refractory thrombotic thrombocytopenic purpura.The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura.Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib.Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura.Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura.Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.Mechanisms of Autoantibody-Induced Pathology.Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patientsManagement of thrombotic thrombocytopenic purpura: current perspectivesBortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.The Tao of myeloma.Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Thrombotic microangiopathies: a general approach to diagnosis and management.Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple MyelomaA combination of bortezomib and rituximab yields a dramatic response in a woman with highly refractory immune thrombocytopenic purpura: a case report.Purtscher retinopathies: are we aiming at the wrong target?Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A.Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model.Pathophysiology of thrombotic thrombocytopenic purpura.Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura.Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.Bortezomib for Reduction of Proteinuria in IgA Nephropathy.Thrombotic thrombocytopenic purpura
P2860
Q30251919-828BD701-EF2F-4BF5-9194-F3807AA38E6DQ33410868-3C1E364B-8521-41D1-ADBE-BF87B9CBBD55Q33414120-476C844F-F29E-4FC7-94F3-E05BBAB6DCD5Q33416780-3A1151FE-F53D-4818-AC43-409DBA630813Q33421268-BBAC37E5-0A49-4AF0-BD5B-B32C62FFDE0BQ33424940-FF2A4068-99F3-43C3-8563-D1F5A71DEF10Q33429298-6B8F9851-F1DA-4886-B103-01D3DAE3BC06Q33430998-B94F402D-94CE-4BAF-8EF6-DA29AC61EC9CQ33432927-F22D72E5-61A3-4039-8F2A-A6B636F87EF8Q33435129-8B2A16FD-B984-46C0-B7E6-92A7E122BD70Q33440605-CFDCE3D7-68D0-463C-9685-4AB4B45D83D9Q33740580-4E70E7A1-6B96-4B10-82D3-ED408019C40FQ34085747-F84382B3-471A-49A9-B9B1-AB8FD9E37F5DQ37577785-CB0A1A15-AFCD-41FF-9BED-C4A0515D8BBFQ37665145-3241AC6B-C9B1-4CFE-9CFC-7A5F1B1E943CQ38237360-8B379157-F294-4BE2-A7BF-5DE9919208E6Q38728585-B7879D42-3780-4FB7-A179-AE4E535A286EQ38984066-3EBD1D63-FC5F-4D7C-9488-0024A8B73F9EQ41657907-D097737C-213D-41C0-8BCF-31B51FD98115Q41868389-E55CCAA2-9E94-4467-98C5-6A7F6646DCAEQ41931368-986595CA-7C55-4218-9B55-68BB0FB2917FQ43126157-86F52AD5-2204-4A5C-88AC-680799729E36Q43716462-DE91AF39-963D-484E-AC22-3ABF0F944414Q45856481-FFC14810-F3BA-45CB-85CC-375BDD9B7E87Q46207877-D0752DB7-C74E-4947-878A-CD21DED60DC8Q47999124-3A683397-69ED-4902-94FF-EDA3A2C4EA92Q48552936-B04A5346-596D-45FB-A35F-A4F6F906D72AQ53303987-7BEAE414-0E52-4533-A797-5F5CD856D13AQ55509819-06B597F8-77B9-468F-B9D9-172FC226FBD4Q57379903-E4830ED4-1E87-4AC9-A7CE-60A5A2894F55
P2860
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
@en
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
@nl
type
label
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
@en
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
@nl
prefLabel
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
@en
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
@nl
P356
P1476
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura
@en
P2093
Stephen S Opat
P356
10.1056/NEJMC1213206
P407
P577
2013-01-01T00:00:00Z